RESEARCH COOPERATION Sample Clauses

RESEARCH COOPERATION. WIPO and ECCAS may take the appropriate measures to conduct research and studies on innovation and disseminate practical information on best practices and technical know-how necessary for fostering development in science, technology, commerce and culture in ECCAS Member States.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
RESEARCH COOPERATION. WIPO and WAEMU may take the appropriate measures to conduct research and studies on innovation and disseminate practical information on best practices and technical know-how necessary for fostering development in science, technology, commerce and culture in WAEMU Member States.
Sample 1Sample 2
RESEARCH COOPERATION. During the Research Term, North Shore will share with CTI data North Shore generates pursuant to the Research Plan on a timely basis and North Shore and CTI will discuss and mutually agree upon priorities, future research to be conducted, and any changes to the Research Plan.
Sample 1Sample 2
RESEARCH COOPERATION. The information provided on contract research also applies to joint results achieved from research cooperation. If, by contrast, this involves results achieved by the indus- try partner or results achieved by the university/research institute, there is no need to issue a separate regulation. However, the group of experts thinks that a separate reg- ulation would need to be issued in respect of joint results if the project manager and other employees of a univer- sity/research institute have a share in the invention that is far lower than 50 percent. If its share in the invention is less than 20 percent, the university/research institute shall desist from participating in the patent application. In this case, the university/research institute has no vested interest in attaining visibility. Contract research (assignment) The applicant status is designed in Clause 9 as a trustee relationship. This highlights the fact that the industry part- ner has substantive rights even though the application is being filed on behalf of the university/research insti- tute (cf. the relevant variant under Clause 8) and also on behalf of the industry partner, as a joint patent applica- tion. In order to pre-empt any disputes between the par- ties, Xxxxxx 9 also stipulates that the initial priority appli- cation must be a German or European patent application. The contracting parties can of course make other arrange- ments. As far as announcing its share in the invention is concerned, the university/research shall be sufficiently pro- tected if it is recognised as a co-applicant within the first 18 months provided the application is filed and published on its behalf. The contractual modules make provision for the rights to be assigned to the industry partner which shall terminate the trustee relationship. Contract research (license) N. B.: from this regulation onwards, the numbering of the types of agreement will also differ, since there is no need to regulate the applicant status in respect of the licence var- iant. This regulation needs to be issued by the university/ research institute.
Sample 1
RESEARCH COOPERATION. 5.1 PURAC shall report to BF semi-annually, with the next report due three (3) months following the Effective Date, on the status of its development efforts, including the progress made in the development effort since the last report and any problems or challenges encountered in developing Licensed Products.
Sample 1
RESEARCH COOPERATION. 6.1. The Parties may collaborate and enter into a research partnership, upon such terms as shall be mutually agreed between the Party REDACTED Parties in good faith.
Sample 1
RESEARCH COOPERATION. 17.1 Know-how transfer. GEAC agrees that GEAC will provide CVUT with necessary know- how, human resources and cooperation for their further development and use according to the Scope of Work and the terms of this Agreement. The Parties have caused this Agreement to be executed in duplicate originals by their duly authorized representatives on the dates set forth below to be effective as of the Effective Date. CZECH TECHNICAL UNIVERSITY GE AVIATION CZECH, S.R.O. IN PRAGUE, FACULTY OF MECHANICAL ENGINEERING By: _ Name: By: _ Name: Title: Title:
Sample 1
AutoNDA by SimpleDocs
RESEARCH COOPERATION. 8.1 Consistent with the existing research cooperation between Schering and AgrEvo, a research cooperation between Schering and the Company shall be established which -- subject to pre-existing contractual obligations vis-a- vis third parties or one of the Parties -- shall provide for a mutual exchange of compounds, libraries and screening possibilities (together the "Compounds"). It is the understanding of the Parties that Schering shall grant to the Company the right of testing the Compounds of Schering and its controlled entities (the "Schering Compounds") for a period of 15 (fifteen) months beginning with the receipt of the Compounds. This also includes the right for the Company to provide the respective legal entities owning the animal health and nutrition businesses of the Aventis group and the Hoechst group (together, the "Aventis Animal Health Businesses") with the Schering Compounds. After expiration of this period, the Company shall have a period of 60 (sixty) days to exercise its rights for an exclusive, worldwide, irrevocable license with the right to sublicense to Affiliates for Schering Compounds in the fields of business of the Company and the Aventis Animal Health Businesses.
Sample 1

Related to RESEARCH COOPERATION

  • Information/Cooperation Executive shall, upon reasonable notice, furnish such information and assistance to the Bank as may be reasonably required by the Bank, in connection with any litigation in which it or any of its subsidiaries or affiliates is, or may become, a party; provided, however, that Executive shall not be required to provide information or assistance with respect to any litigation between Executive and the Bank or any other subsidiaries or affiliates.

  • Regulatory Cooperation In connection with any foreclosure, collection, sale or other enforcement of Liens granted to the Administrative Agent in the Collateral Documents, Parent will, and will cause its Restricted Subsidiaries to, reasonably cooperate in good faith with the Administrative Agent or its designee in obtaining all regulatory licenses, consents and other governmental approvals necessary or (in the reasonable opinion of the Administrative Agent or its designee) reasonably advisable to conduct all aviation operations with respect to the Collateral and will, at the reasonable request of the Administrative Agent and in good faith, continue to operate and manage the Collateral and maintain all applicable regulatory licenses with respect to the Collateral until such time as the Administrative Agent or its designee obtain such licenses, consents and approvals, and at such time Parent will, and will cause its Restricted Subsidiaries to, cooperate in good faith with the transition of the aviation operations with respect to the Collateral to any new aviation operator (including, without limitation, the Administrative Agent or its designee).

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Scope of Cooperation 1. The Authorities recognise the importance of close communication concerning the Covered CCPs and intend to cooperate regarding:

  • Information and Cooperation Each Party that has responsibility for filing and prosecuting any Patent Rights under this Section 7.4 (a “Filing Party”) shall (a) regularly provide the other Party (the “Non-Filing Party”) with copies of all patent applications filed hereunder and other material submissions and correspondence with the patent offices, in sufficient time to allow for review and comment by the Non-Filing Party; and (b) provide the Non-Filing Party and its patent counsel with an opportunity to consult with the Filing Party and its patent counsel regarding the filing and contents of any such application, amendment, submission or response. The advice and suggestions of the Non-Filing Party and its patent counsel shall be taken into consideration in good faith by such Filing Party and its patent counsel in connection with such filing. Each Filing Party shall pursue in good faith all reasonable claims and take such other reasonable actions, as may be requested by the Non-Filing Party in the prosecution of any Patent Rights covering any Program Technology under this Section 7.4; provided, however, if the Filing Party incurs any additional expense as a result of any such request, the Non-Filing Party shall be responsible for the cost and expenses of pursuing any such additional claim or taking such other actions. In addition, Company agrees that if Licensor claims any action taken under Section 7.4(d)(i) would be detrimental to Patent Rights covering Licensor Technology, Licensor shall provide written notice to Company and the Patent Coordinators shall, as promptly as possible thereafter, meet to discuss and resolve such matter and, if they are unable to resolve such matter, the Parties shall refer such matter to a mutually agreeable outside patent counsel for resolution.

  • Regulatory Compliance Cooperation (a) CIT/VC agrees to use commercially reasonable best efforts to avoid the occurrence of a Regulatory Problem. In the event that CIT/VC determines that it has a Regulatory Problem, the Company agrees to use commercially reasonable efforts to take all such actions as are reasonably requested by CIT/VC in order (A) to effectuate and facilitate any transfer by CIT/VC of any Securities of the Company then held by CIT/VC to any Person designated by CIT/VC (subject, however, to compliance with Section 3 of this Agreement), (B) to permit CIT/VC (or any Affiliate of CIT/VC) to exchange all or any portion of the voting Securities of the Company then held by such Person on a share-for-share basis for shares of a class of non-voting Securities of the Company, which non-voting Securities shall be identical in all respects to such voting Securities, except that such new Securities shall be non-voting and shall be convertible into voting Securities on such terms as are requested by CIT/VC in light of regulatory considerations then prevailing, and (C) to continue and preserve the respective allocation of the voting interests with respect to the Company arising out of CIT/VC's ownership of voting Securities of the Company and/or provided for in this Agreement before the transfers and amendments referred to above (including entering into such additional agreements as are requested by CIT/VC to permit any Person(s) designated by CIT/VC to exercise any voting power which is relinquished by CIT/VC upon any exchange of voting Securities for nonvoting Securities of the Company); and the Company shall enter into such additional agreements, adopt such amendments to this Agreement, the Company's Charter and the Company's By-laws and other relevant agreements and taking such additional actions, in each case as are reasonably requested by CIT/VC in order to effectuate the intent of the foregoing. If CIT/VC elects to transfer Securities of the Company to a Regulated Holder in order to avoid a Regulatory Problem, the Company shall enter into such agreements with such Regulated Holder as it may reasonably request in order to assist such Regulated Holder in complying with applicable laws, and regulations to which it is subject. Such agreements may include restrictions on the 39. redemption, repurchase or retirement of Securities of the Company that would result or be reasonably expected to result in such Regulated Holder holding more voting securities or total securities (equity and debt) than it is permitted to hold under such laws and regulations.

  • Assistance and Cooperation After the Closing Date, each of Seller and Purchaser shall:

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!